Suppr超能文献

RESUME-1:托培酮治疗背部疼痛性急性肌肉痉挛的 III 期研究。

RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back.

机构信息

Neurana Pharmaceuticals, Inc., San Diego, CA 92122, USA.

出版信息

Pain Manag. 2022 Jan;12(1):25-33. doi: 10.2217/pmt-2021-0041. Epub 2021 Jul 1.

Abstract

Tolperisone is a nonopioid, centrally acting muscle relaxant in clinical development in the USA for the treatment of symptoms associated with acute, painful muscles spasms of the back. CLN-301, RESUME-1, is a 14-day double-blind, randomized, placebo-controlled, parallel-group Phase III study of the efficacy and safety of tolperisone administered orally three-times daily in 1000 male and female subjects at approximately 70 clinical sites in the USA experiencing back pain due to or associated with muscle spasm of acute onset. Tolperisone is a promising therapeutic for managing acute, painful muscle spasms of the back as it appears to lack the off-target CNS effects often seen with conventional skeletal muscle relaxants. .

摘要

托哌酮是一种非阿片类、中枢作用的肌肉松弛剂,目前正在美国进行临床开发,用于治疗与急性、疼痛性背部肌肉痉挛相关的症状。CLN-301(RESUME-1)是一项为期 14 天的、双盲、随机、安慰剂对照、平行分组的 III 期研究,旨在评估托哌酮口服每日三次在大约 70 个美国临床中心的 1000 名男性和女性受试者中的疗效和安全性,这些受试者因急性发作的肌肉痉挛或与之相关的背部疼痛而接受治疗。托哌酮是一种有前途的治疗急性、疼痛性背部肌肉痉挛的药物,因为它似乎缺乏传统骨骼肌松弛剂常见的非靶标中枢神经系统效应。

相似文献

1
RESUME-1: a Phase III study of tolperisone in the treatment of painful, acute muscle spasms of the back.
Pain Manag. 2022 Jan;12(1):25-33. doi: 10.2217/pmt-2021-0041. Epub 2021 Jul 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验